Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Qatar.
Campus
Campus

Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases

Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.

Related articles
When DUPIXENT is available, I would say go for it
  • Nasal Polyps

When DUPIXENT is available, I would say go for it

Read article
What can biologic treatment do for patients with CRS with nasal polyps?
  • Nasal Polyps

What can biologic treatment do for patients with CRS with nasal polyps?

Read article
Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery
  • Nasal Polyps

Rethink Your Nasal Polyps. Type 2 Inflammation A Nasal Polyp Mystery

Read article
MAT-BH-2300373/V1/JUNE 2023